RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2003; 128(43): 2253-2256
DOI: 10.1055/s-2003-43098
DOI: 10.1055/s-2003-43098
Arzneistoff
© Georg Thieme Verlag Stuttgart · New York
Citalopram
CitalopramWeitere Informationen
Publikationsverlauf
eingereicht: 31.7.2003
akzeptiert: 18.8.2003
Publikationsdatum:
23. Oktober 2003 (online)

Citalopram (Cipramil®, Sepram® und zahlreiche Generika) ist ein zur chemischen Klasse der bizyklischen Isobenzofuran-Derivate gehörender selektiver Serotonin-Wiederaufnahme-Hemmer (SSRI, Abb. [1]). Es wurde 1996 in Deutschland zur Behandlung depressiver Erkrankungen und Panikstörungen zugelassen.
Abb.1 Struktur von Citalopram.
Literatur
- 1 Keller M B. Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials. J Clin Psychiatry. 2000; 61 896-908
- 2 Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984; 230 94-102
- 3 Milne R J, Goa K L. Citalopram: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991; 41 450-477
- 4 Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996; 11 5-11
- 5 Melzacka M, Rurak A, Adamus A, Daniel W. Distribution of citalopram in the blood serum and in the central nervous system of rats after single and multiple dosage. Pol J Pharmacol Pharm. 1984; 36 675-682
-
6 Fachinformation: Citalopram (Sepram®); Stand September 2001
- 7 Brosen K, Naranjo C A. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001; 11 275-283
- 8 Montgomery S A, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo controlled studies. Int Clin Psychopharmacol. 1994; 9 35-40
- 9 Parker N G, Brown C S. Citalopram in the treatment of depression. Ann Pharmacother. 2000; 34 761-771
- 10 Feighner J P, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry. 1999; 60 824-830
- 11 Mendels J, Kiev A, Fabre L F. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety. 1999; 9 54-60
- 12 Pollock B G. Citalopram: a comprehensive review Expert. Opin Pharmacother. 2001; 2 681-698
- 13 Patris M, Bouchard J M, Bougerol T, Charbonnier J F, Chevalier J F, Clerc G. et al . Citalopram versus fluoxetine: a double-blind, controlled, multicenter, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol. 1996; 11 129-136
- 14 Haffmans P MJ, Timmerman L, Hooqduin C A. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicenter study. Int Clin Psychopharmacol. 1996; 11 157-164
- 15 Ekselius L, von Knorring L, Eberhand G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol. 1997; 12 323-331
- 16 de Wilde J, Mertens C, Overo K F, Petersen H E. Citalopram versus mianserin: A controlled, double-blind trial in depressed patients. Acta Psychiatr Scand. 1985; 72 89-96
- 17 Ahlfors U G, Elovaura S, Harma P. et al . Clinical multi-centre study of citalopram compared double-blindly with mianserin in depressed patients in Finland. Nord Psykiatr Tidsskr. 1988; 42 201
- 18 Bouchard J M, Delaunay J, Delisle J P, Grasset N, Mermberg P F, Molczadzki M, Pagot R, Richou H, Robert G, Ropert R. et al . Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. Acta Psychiatr Scand. 1987; 76 583-592
- 19 Rosenberg C, Damsbo N, Fuglum E, Jacobsen L V, Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicenter study. Int Clin Psychopharmacol. 1994; 9 41-48
- 20 Shaw D M, Thomas D R, Briscoe M H, Watkins S E, Crimmins R. A comparison of the antidepressant action of citalopram and amitriptyline. Br J Psychiatry. 1986; 149 515-517
- 21 Gravem A, Amthor K F, Astrup C, Elgen K, Gjessing L R, Gunby B. et al . A double-blind comparison of citalopram (Lu 10 - 171) and amitriptyline in depressed patients. Acta Psychiatr Scand. 1987; 75 478-486
- 22 Danish University Antidepressant Group . Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl). 1986; 90 131-138
- 23 Baumann P, Nil R, Bertschy G, Jecker A, Brandli H, Morand J, Kasas A, Vuagniaux O, Ramseier F. A double-blind double-dummy study of citalopram comparing infusion versus oral administration. J Affect Disord. 1998; 49 203-210
- 24 Guelfi J D, Strub N, Loft H. Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety andefficacy data from a double-blind, double-dummy trial. J Affect Disord. 2000; 58 201-209
- 25 Montgomery S A, Rasmussen J G, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol. 1993; 8 181-188
- 26 Wade A G, Lepola U, Koponen H J, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry. 1997; 170 549-553
- 27 Ostrom M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram. Lancet. 1996; 348 339-340
-
28 Arzneimittel-Telegramm 1996 96: 106-107
- 29 Rasmussen S L, Overo K F, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol. 1999; 19 407-415
- 30 Meuleman C, Jourdain P, Bellorini M, Sadeg N, Loiret J, Guillard N, Thebault B, Funck F. Citalopram and Torsades de Pointes: A case report. Arch Mal Coeur Vaiss. 2001; 94 1021-1024
- 31 Catalano G, Catalano M C, Epstein M A, Tsambiras P E. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol. 2001; 24 158-156
- 32 Rothenhausler H B, Hoberl C, Ehrentrout S, Kapfhammer H P, Weber M M. Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatry. 2000; 33 150-152
- 33 Barbey J T, Roose S P. SSRI safety in overdose. J Clin Psychiatry. 1998; 59 42-48
- 34 Waugh J, Goa K L. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003; 17 343-362
- 35 Lepola U M, Loft H, Reines E H. Escitalopram (10 - 20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2003; 18 211-217
- 36 Laux G, Dietmaier O, König W. Pharmakopsychiatrie. Urban und Fischer Verlag 2001
- 37 Greenblatt D J, von Moltke L L, Harmatz J S, Shader R I. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry. 1998; 59 (Suppl 15) 19-27
- 38 Dalton S O, Johansen C, Mellemkjaer L, Norgard B, Sorensen H T, Olsen J H. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003; 163 59-64
- 39 de Abajo F J, Rodriguez L A, Montero D S. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999; 319 1106-9
Prof. Dr. Thomas Eschenhagen
Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg